

Policies Repository



Policy Title Tramadol Extended-Release (ER) (Ultram ER®)

Policy Number FS.CLIN.9

Application of Pharmacy Policy is determined by benefits and contracts. Benefits may vary based on product line, group or contract. Some medications may be subject to precertification, age, gender or quantity edits. Individual member benefits must be verified.

This Pharmacy Policy document describes the status of pharmaceutical information and/or technology at the time the document was developed. Since that time, new information relating to drug efficacy, interactions, contraindications, dosage, administration routes, safety or FDA approval may have changed. If the Medical/Pharmacy Reviewer is aware of any new information on the subject of this document, please provide it promptly to the Medical/Pharmacy Policy Department. This information may include new FDA approved indications, withdrawals or other FDA alerts. This type of information is relevant not only when considering whether this Policy should be updated, but also when applying it to current requests for coverage.

Members are advised to use participating pharmacies in order to receive the highest level of benefits.

Policy **Tramadol extended-release (ER) (Ultram ER®)** is indicated for the management of moderate to moderately severe chronic pain in adults who require continuous pain relief for an extended period of time.

The use of the brand name Ultram ER® requires prior authorization (ie, clinical pharmacy and/or Medical Director review).

Policy Description

Tramadol extended-release (ER) (Ultram ER®) is a centrally acting synthetic opioid analgesic. Although its mode of action is not completely understood, at least two complementary mechanisms appear to be applicable during animal testing: binding of parent and M1 metabolites to μ -opioid receptors and weak inhibition of reuptake of norepinephrine and serotonin. In four 12-week, randomized, double-blind, placebo-controlled trials, tramadol ER (Ultram ER®) was studied in individuals with moderate to moderately severe chronic pain due to osteoarthritis and/or lower back pain. All four trials concluded that tramadol ER (Ultram ER®) was significantly better than the placebo in alleviating chronic pain. No trials have been conducted to compare tramadol ER (Ultram ER®) with other analgesic agents.

Policy Guideline Inclusion

Tramadol extended-release (ER) (Ultram ER®) is approved when the following inclusion criteria is met:

- Documentation of a trial and failure of or intolerance to generic tramadol extended release

Policy Guideline Exclusion

Tramadol extended-release (ER) (Ultram ER®) is denied when the following exclusion criteria is present:

- No documentation of a trial and failure of or intolerance to generic

tramadol extended release

Policy List of Applicable Drugs

Brand Name	Generic Name
Ultram ER	tramadol ER

Dosing and Administration

Refer to the specific manufacturer's prescribing information for administration and dosage details for each specific agent.

Policy References

Facts and Comparisons. Ultram ER® (tramadol). [Facts and Comparisons Web site]. Available at: <http://www.factsandcomparisons.com/efacts.asp> [via subscription only]. Accessed March 19, 2010.

Tramadol extended-release. In: *DrugPoints* [online through STAT! Ref]. Greenwood Village, CO: Thompson Micromedex. Available at: <http://www.thomsonhc.com> [via subscription only]. Accessed March 19, 2010.

Ultram ER® [prescribing information]. Raritan, NJ: Ortho-McNeil; 2007. Also available online at: <http://www.ultram-er.com/ultram-er/shared/pi/ultram-er.pdf#zoom=100>. Accessed March 19, 2010.

Policy Link to Related Policies**Printed**

09/07/2010 13:23:37

The Policy Bulletins on this web site were developed to assist Independence Blue Cross and its subsidiaries ("IBC") in administering the provisions of the respective benefit programs, and do not constitute a contract. If you are an IBC member, please refer to your specific benefit program for the terms, conditions, limitations and exclusions of your coverage. IBC does not provide health care services, medical advice or treatment, or guarantee the outcome or results of any medical services/treatments. The facility and professional providers are responsible for providing medical advice and treatment. Facility and professional providers are independent contractors and are not employees or agents of IBC. If you have a specific medical condition, please consult with your doctor. IBC reserves the right at any time to change or update its Policy Bulletins. © 2008 Independence Blue Cross. All Rights Reserved. Current Procedural Terminology © 2008 American Medical Association. All Rights Reserved.